Beam Therapeutics filed a lawsuit accusing YolTech and Serapha Bio of stealing trade secrets tied to base-editing programs. The complaint alleges a former Beam scientist accessed the company’s electronic laboratory notebooks and helped launch a competing therapy that was later licensed to Serapha. The suit reflects escalating tensions between U.S. genome-editing startups and Chinese competitors, particularly around IP protections, data access, and how early discovery work can be replicated across borders. For biotech investors and operators, the case highlights how foundational model-building platforms in genome editing can quickly become the focus of disputes—potentially influencing partnership diligence, IP strategy, and litigation risk pricing.